299 related articles for article (PubMed ID: 16427862)
1. Effect of aprotinin and recombinant variants on platelet protease-activated receptor 1 activation.
Day JR; Haskard DO; Taylor KM; Landis RC
Ann Thorac Surg; 2006 Feb; 81(2):619-24. PubMed ID: 16427862
[TBL] [Abstract][Full Text] [Related]
2. The antithrombotic effect of aprotinin: actions mediated via the proteaseactivated receptor 1.
Poullis M; Manning R; Laffan M; Haskard DO; Taylor KM; Landis RC
J Thorac Cardiovasc Surg; 2000 Aug; 120(2):370-8. PubMed ID: 10917956
[TBL] [Abstract][Full Text] [Related]
3. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery.
Day JR; Punjabi PP; Randi AM; Haskard DO; Landis RC; Taylor KM
Circulation; 2004 Oct; 110(17):2597-600. PubMed ID: 15262827
[TBL] [Abstract][Full Text] [Related]
4. Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction.
Day JR; Landis RC; Taylor KM
Semin Cardiothorac Vasc Anesth; 2006 Jun; 10(2):132-42. PubMed ID: 16959740
[TBL] [Abstract][Full Text] [Related]
5. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1.
Day JR; Taylor KM; Lidington EA; Mason JC; Haskard DO; Randi AM; Landis RC
J Thorac Cardiovasc Surg; 2006 Jan; 131(1):21-7. PubMed ID: 16399290
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
7. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PAR4 signaling mediates ethanol-induced attenuation of platelet function in vitro.
Kasuda S; Sakurai Y; Shima M; Morimura Y; Kudo R; Takeda T; Ishitani A; Yoshioka A; Hatake K
Alcohol Clin Exp Res; 2006 Sep; 30(9):1608-14. PubMed ID: 16930224
[TBL] [Abstract][Full Text] [Related]
9. The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1.
Nieman MT; Warnock M; Hasan AA; Mahdi F; Lucchesi BR; Brown NJ; Murphey LJ; Schmaier AH
J Pharmacol Exp Ther; 2004 Nov; 311(2):492-501. PubMed ID: 15210836
[TBL] [Abstract][Full Text] [Related]
10. Invited commentary.
Rinder HM
Ann Thorac Surg; 2006 Feb; 81(2):624. PubMed ID: 16427863
[No Abstract] [Full Text] [Related]
11. Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development.
Vretenbrant K; Ramström S; Bjerke M; Lindahl TL
Thromb Haemost; 2007 Mar; 97(3):417-24. PubMed ID: 17334509
[TBL] [Abstract][Full Text] [Related]
12. Aprotinin inhibits protease-dependent platelet aggregation and thrombosis.
Khan TA; Bianchi C; Voisine P; Sandmeyer J; Feng J; Sellke FW
Ann Thorac Surg; 2005 May; 79(5):1545-50. PubMed ID: 15854931
[TBL] [Abstract][Full Text] [Related]
13. Characterization of plasmin-induced platelet aggregation.
Watabe A; Ohta M; Matsuyama N; Mizuno K; el Borai N; Tanimoto T; Kawanishi T; Hayakawa T
Res Commun Mol Pathol Pharmacol; 1997 Jun; 96(3):341-52. PubMed ID: 9261893
[TBL] [Abstract][Full Text] [Related]
14. The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation.
Tanaka KA; Szlam F; Levy JH
Br J Haematol; 2006 Jul; 134(1):77-82. PubMed ID: 16803571
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel peptide inhibitors of thrombin-induced platelet activation.
Burke FM; Warnock M; Schmaier AH; Mosberg HI
Chem Biol Drug Des; 2006 Nov; 68(5):235-8. PubMed ID: 17177882
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil proteases can inactivate human PAR3 and abolish the co-receptor function of PAR3 on murine platelets.
Cumashi A; Ansuini H; Celli N; De Blasi A; O'Brien PJ; Brass LF; Molino M
Thromb Haemost; 2001 Mar; 85(3):533-8. PubMed ID: 11307827
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3.
Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Lee CY; Teng CM
Thromb Haemost; 2002 Jun; 87(6):1026-33. PubMed ID: 12083482
[TBL] [Abstract][Full Text] [Related]
19. Protease activated receptors: clinical relevance to hemostasis and inflammation.
Landis RC
Hematol Oncol Clin North Am; 2007 Feb; 21(1):103-13. PubMed ID: 17258121
[TBL] [Abstract][Full Text] [Related]
20. Protease-activated receptor 4 uses anionic residues to interact with alpha-thrombin in the absence or presence of protease-activated receptor 1.
Nieman MT
Biochemistry; 2008 Dec; 47(50):13279-86. PubMed ID: 19053259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
